Adlai Nortye expands Phase I testing of AN4035, adding Lilly-supplied cetuximab in a new global collaboration

Adlai Nortye is broadening the early-stage clinical work behind AN4035, an investigational antibody-drug conjugate strategy designed to inhibit pan-RAS(ON) indicating. In a collaboration announced through market channels, the company said AN4035 will be studied as a monotherapy and also in combination with cetuximab, using an ongoing global Phase I trial structure.

The program centers on a Phase I clinical study that is already underway. According to the announcement circulated by Yahoo Finance, the trial will test AN4035 by itself and explore whether combining AN4035 with cetuximab can improve clinical activity or deepen mechanistic indicates compared with single-agent therapy.

Cetuximab, the monoclonal antibody referenced in the collaboration, is an established cancer therapy that is commonly used in combination regimens and in trials targeting epidermal growth factor receptor (EGFR) pathways. In this case, Lilly’s role is described as supplying cetuximab for the study, aligning Lilly’s downstream manufacturing and trial support capabilities with Adlai Nortye’s investigational ADC-based approach.

Under the partnership described in the report, Lilly and Merck KGaA, Darmstadt, Germany are included as collaborators alongside Adlai Nortye. While the announcement identifies the participating parties and the trial configuration, it does not spell out how responsibilities are divided for functions such as regulatory operations, data analysis, or country-by-country enrollment management.

AN4035 is characterized in the announcement as a first-in-class investigational pan-RAS(ON) inhibitor-based ADC. In plain terms, that means the drug combines a targeting antibody component with a payload intended to modulate RAS(ON) biology in tumor cells, with the goal of concentrating anti-cancer effects where the antibody binds. The mention of “pan-RAS(ON)” suggests the strategy aims to cover multiple RAS activation states or related indicating behaviors, though the specific biology and how it is measured in humans is not detailed in the circulated post.

The trial approach described in the report reflects a typical early development pattern in oncology drug research. Companies frequently begin with single-agent dosing to characterize safety, tolerability, and pharmacodynamic indicates, then add combination arms to test whether a partner therapy, such as cetuximab, may provide complementary pathway inhibition. The global Phase I design also suggests the sponsors are seeking broader patient diversity and faster announcement generation across geographies.

For Eli Lilly, involvement as a cetuximab supplier for an external trial can be an operational pathway to support combination research without necessarily disclosing a direct therapeutic claim for the investigational partner. For Merck KGaA, Darmstadt, Germany, being named in the collaboration points to a shared interest in the development of combination oncology regimens, although the reported materials do not specify whether Merck KGaA contributes assets beyond partnership participation.

What is not disclosed in the circulated announcement includes the financial terms of the collaboration, the expected size of the dose-escalation and expansion portions of the Phase I study, specific tumor types targeted in the trial, enrollment timelines, and the primary clinical endpoints the sponsors plan to emphasize. The post also does not provide any updated safety or efficacy readouts from the ongoing study.

Investors and clinicians following the program will likely focus on forthcoming trial updates that report tolerability across escalating doses, any dose-limiting toxicities, and early evidence of anti-tumor activity in the monotherapy versus combination arms. Additional detail on how the sponsors plan to evaluate the pharmacology of AN4035 and the biological response to the cetuximab combination will be key to judging whether the regimen can move forward into larger studies.